Lumen Bioscience Announces $5.5 Million Funding to Support New Research Program for Mucosal Vaccine Platform Technology

by admin | Nov 29, 2023 | Press Release

– Program aims to provide new technologies for overcoming a key biological limitation in needle-free vaccines Seattle, WA, November 29, 2023 – Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent...

Reinventing How Drugs Are Invented: Making a Case for Simplicity in Drug Development and Production

by admin | Nov 17, 2023 | Publications

Read here

Lumen Bioscience secures DOD funding for infection treatment

by admin | Oct 22, 2023 | Press Release

Lumen Bioscience co-founder and CEO Brian Finrow said the company is looking for people newly diagnosed with the infection for its trials. Read More

Lumen Bioscience awarded $16.2 million to advance C. difficile treatment

by admin | Oct 17, 2023 | Press Release

Read More

Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials

by admin | Oct 16, 2023 | Press Release

— Orally delivered biologic drug to treat and prevent C. difficile infection to start recruiting for late-stage trials in Q4 2023 Seattle, WA, October 17, 2023 – Lumen Bioscience—a clinical-stage biotechnology company developing biologic drugs for highly prevalent...